Inhibitor Therapeutics Inc INTI
$0.09
Last Updated: Aug 19, 12:00 AM·OOTC
Pricing for US stocks is delayed by 24 hours
INTI Shariah Compliance
Screening Methodology: AAOIFI
As of August 2026, Inhibitor Therapeutics Inc is classified as not halal.
NOT HALAL
Report Source: undefined Quarter Report
Inhibitor Therapeutics Inc. Stock Analysis INTI
United States Health Care Nano Cap Inhibitor Therapeutics, Inc. engages in the discovery, development, and commercialization of therapeutics for patients with cancer. The company is headquartered in Tampa, Florida and currently employs 2 full-time employees. The firm is focused on developing and commercializing therapeutics based on already approved active pharmaceuticals that have patent-protected methods of use and/or methods of delivery for patients with certain cancers and certain non-cancerous proliferation disorders. Its primary focus is on the development of therapies initially for basal cell carcinoma (BCC), prostate and lung cancers in the United States utilizing itraconazole, a drug approved by the United States Food and Drug Administration (FDA) to treat fungal infections. The firm has developed intellectual property and know-how related to the treatment of cancer patients using itraconazole. The firm's intellectual property in the form of issued United States patents includes treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors, and treatment of lung cancer using hedgehog pathway inhibitors.
Inhibitor Therapeutics Inc (INTI) Chart
Financial Metrics & Statements of Inhibitor Therapeutics Inc (INTI)
FAQ's for Inhibitor Therapeutics Inc (INTI)
- As of August 2026, Inhibitor Therapeutics Inc INTI is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Inhibitor Therapeutics Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Inhibitor Therapeutics Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Inhibitor Therapeutics Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Inhibitor Therapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Inhibitor Therapeutics Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Alternate Halal Stocks for Inhibitor Therapeutics Inc (INTI)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
